Literature DB >> 31604671

Automated Referral to Cardiac Rehabilitation After Coronary Artery Bypass Grafting Is Associated With Modest Improvement in Program Completion.

Hongwei Liu1, Stephen B Wilton2, Danielle A Southern3, Merril L Knudtson4, Andrew Maitland4, Trina Hauer5, Ross Arena6, Codie Rouleau7, Matthew T James8, James Stone9, Sandeep Aggarwal10.   

Abstract

BACKGROUND: Cardiac rehabilitation (CR) is a guideline-indicated modality for reducing residual cardiovascular risk among patients undergoing coronary artery bypass grafting (CABG) surgery. However, many referred patients do not initiate or complete a CR program; even more patients are never even referred.
METHODS: All post-CABG patients in Calgary, Alberta, Canada, from January 1, 1996, to March 31, 2016, were included. Data were obtained from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease and TotalCardiology Rehabilitation databases. Automated referral to CR at discharge after CABG was instituted on July 1, 2007. We used interrupted time series analysis to evaluate the impact of automated referral on CR referral and completion rates and studied the association of these CR process markers with mortality.
RESULTS: A total of 8,118 patients underwent CABG surgery during the study period: 5,103 before automation and 3,015 after automation. Automation increased referral rates from 39.5% to 75.0% (P < 0.001). Automated referral was associated with a 7.2% increase in CR completion in the overall population (33.3% vs 26.1%; P < 0.001). In adjusted models, CR referral alone was not associated with reduced mortality (hazard ratio [HR] 0.84, 95% CI 0.64-1.11), but CR completion was (HR 0.43, 95% CI 0.31-0.61).
CONCLUSION: Automated referral in post-CABG patients resulted in modest improvement in CR program completion. Therefore, even when CR referral is automated to include all eligible patients, additional strategies to support CR program enrollment and completion remain necessary to achieve the desired health benefits.
Copyright © 2019 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 31604671     DOI: 10.1016/j.cjca.2019.08.008

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  6 in total

Review 1.  Cardiac Rehabilitation: Under-Utilized Globally.

Authors:  Sherry L Grace; Kornelia Kotseva; Mary A Whooley
Journal:  Curr Cardiol Rep       Date:  2021-07-16       Impact factor: 2.931

Review 2.  Current challenges in cardiac rehabilitation: strategies to overcome social factors and attendance barriers.

Authors:  Shahzad Chindhy; Pam R Taub; Carl J Lavie; Jia Shen
Journal:  Expert Rev Cardiovasc Ther       Date:  2020-09-14

Review 3.  Enhancing participation in cardiac rehabilitation: Focus on underserved populations.

Authors:  Philip A Ades; Sherrie Khadanga; Patrick D Savage; Diann E Gaalema
Journal:  Prog Cardiovasc Dis       Date:  2022-01-31       Impact factor: 11.278

4.  Baseline factors identified for the prediction of good responders in patients with end-stage diffuse coronary artery disease undergoing intracoronary CD34+ cell therapy.

Authors:  Pei-Hsun Sung; Hsin-Ju Chiang; Yi-Chen Li; John Y Chiang; Chi-Hsiang Chu; Pei-Lin Shao; Fan-Yen Lee; Mel S Lee; Hon-Kan Yip
Journal:  Stem Cell Res Ther       Date:  2020-07-29       Impact factor: 6.832

5.  A nationwide survey on participation in cardiac rehabilitation among patients with coronary heart disease using health claims data in Japan.

Authors:  Shosuke Ohtera; Genta Kato; Hiroaki Ueshima; Yukiko Mori; Yuka Nakatani; Neiko Ozasa; Takeo Nakayama; Tomohiro Kuroda
Journal:  Sci Rep       Date:  2021-10-11       Impact factor: 4.379

6.  Trends in cardiac rehabilitation enrollment post-coronary artery bypass grafting upon implementation of automatic referral in Southeast Asia: A retrospective cohort study.

Authors:  Karen V Miralles-Resurreccion; Sherry L Grace; Lucky R Cuenza
Journal:  J Cardiovasc Thorac Res       Date:  2022-06-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.